Latest Oblique Therapeutics News & Updates

See the latest news and media coverage for Oblique Therapeutics. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Oblique Therapeutics

Biotech developing antibodies for pain and cancer

obliquet.com
Headquarters
Göteborg, Sweden
Founded year
2015
Company type
Private company
Number of employees
2–10

Latest news about Oblique Therapeutics

Company announcements

  • Oblique Therapeutics

    Oblique Therapeutics announces conversion of mandatory convertibles

    Convertibles of 15.8 MSEK are converted to 10.5 million new A-shares, increasing the number of shares to 56.2 million with 18.77% dilution.

  • Oblique Therapeutics

    Oblique Therapeutics announces the outcome of the convertible bond issue

    The issue was subscribed to 95.4% of 14.5 MSEK. Convertibles are converted in 2026 to shares with 25.6% dilution.

  • Oblique Therapeutics

    Oblique Therapeutics publishes supplementary prospectus

    The addition is approved by the Financial Supervisory Authority due to errors in the conversion rates. Investors can withdraw their subscription until 25 June 2025.

  • Oblique Therapeutics

    Oblique Therapeutics postpones the subscription period in the convertible issue

    The reason is the delayed registration of the prospectus with the Financial Supervisory Authority. The terms are unchanged except for the maturity.

Unlock all announcements with a

Media coverage

  • Dagens industri

    Oblique Therapeutics announces conversion of mandatory convertibles

    The board of directors of Oblique Therapeutics AB (publ) ("Oblique Therapeutics" or "the Company") announces that all convertibles issued within the framework of...

  • Dagens industri

    Oblique Therapeutics announces today that the company has carried out a targeted cost reduction

    "We have carried out necessary and structural changes to optimize our capital use and at the same time ensure that we fully prioritize what has the greatest value creation...

  • Dagens industri

    Oblique Therapeutics carries out an issue of convertibles of approximately 15.2 MSEK primarily directed to existing shareholders

    Oblique Therapeutics has developed a patented technology, AbiProt®, with which one can identify areas on target proteins in the cell membrane where antibodies can bind. Information regarding these...

Unlock all articles with a

Never miss news about Oblique Therapeutics

Track Oblique Therapeutics and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Oblique Therapeutics competitors & trending companies

Browse news for competitors to Oblique Therapeutics and other trending companies.